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Abstract
At a workshop in Leuven, November 8-10, 1996, 24 clinical and laboratory 
geneticists from 15 countries in Europe met and discussed minimum stan­
dards for prenatal diagnosis. These guidelines are intended for use as a refer­
ence manual by genetic centres all over Europe, especially in countries without 
national guidelines, in their efforts to achieve and maintain high standards. 
The workshop was restricted to discuss quality assessment on established 
invasive procedures for cytogenetic and molecular studies. The committee 
brought together from their own countries substantial experience of genetic 
counselling, cytogenetics, molecular biology and quality assessment. It is 
hoped that future discussions, embracing all aspects of clinical and laboratory 
genetic services will lead to the establishment of common guidelines for all 
European countries.
Introduction
Effective diagnosis of genetic diseases depends on the 
skills of a multidisciplinary team with a wide range of 
clinical and laboratory experience. Three types of labora­
tory investigation can be distinguished: cytogenetic, bio­
chemical and molecular; the majority of genetic diagnos­
tic prenatal tests are cytogenetic, sometimes performed by 
specialised laboratories, while other types of investigation 
generally comprise a minor part of the clinical workload 
of a molecular or biochemical laboratory.
EUCROMIC is an EU concerted action (contract No. BMH-CT93-1673).
With the expanding knowledge of their underlying 
cause, and the introduction of novel techniques such as 
fluorescence in situ hybridisation (FISH), an increasing 
number of human genetic disorders are amenable to pre­
natal diagnosis, thus raising the demand for clinical inves­
tigations and the need for adequate control of laboratory 
procedures and consideration of ethical issues.
The risks attached to invasive testing and the conse­
quence of abnormal laboratory results require detailed 
and sympathetic explanation to the patient. Therefore, a 
vital component in prenatal diagnosis must be expert 
counselling of the patient by an experienced clinician 
before sampling and, also in the event of an abnormal 
result, afterwards.
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With regard to genetic disorders detected by molecular 
techniques, prenatal testing must be seen within the con­
text of the family; it is essential to have prior knowledge, 
from an existing family study, of the particular mutation 
or mutations to be studied and the expected segregation
pattern.
These guidelines, drawn up at a workshop in Leuven, 
November 8-10, 1996, by 24 clinical and laboratory 
geneticists from 15 countries in Europe, are intended for 
use as a reference manual by genetic centres in their 
efforts to achieve and maintain high standards. The com­
mittee brought together from their own countries substan­
tial experience of genetic counselling, cytogenetics, molec­
ular biology and quality assurance. Participants are listed 
in Appendix 1. It is hoped that future discussions, em­
bracing all aspects of clinical and laboratory genetic ser­
vices will lead to the establishment of common guidelines 
for all European countries. The workshop was restricted 
to discussions of quality assessment on fetal samples 
obtained by established invasive procedures for cytoge­
netic and molecular studies. Thus, issues such as bio­
chemical screening during pregnancy or investigations 
that still might be considered to be under development 
were not discussed.
While methodology and techniques are developing 
rapidly, frequent revisions to these guidelines are envis­
aged. There is also a need to discuss the development of 
external quality assessment programmes, responsibilities 
which fall to the scientific and clinical genetic communi­
ties. The formation of pan-European external quality 
assessment (EQA) networks such as the European Molec­
ular Genetics Quality Network (EMQN) are therefore 
strongly endorsed.
As well as drawing on experience and knowledge, these 
guidelines take account of existing quality assessment 
(QA) schemes, good laboratory practice (GLP) docu­
ments, and accreditation procedures and protocols from 
different countries. Existing national guidelines in the dif­
ferent European countries are outlined in brief below. The 
documents referred to when developing these guidelines, 
listed in Appendix 2, are available from national profes­
sional organisations. A general presentation of clinical 
genetic services and the current status of prenatal diagno­
sis in Europe are to be found in recent publications from 
the EU sponsored concerted actions CAGSE (Concerted 
Action on Genetic Services in Europe) [1] and EU- 
CROMIC (European Collaborative Research on Mosai­
cism in CVS) [2].
This report includes aspects of quality control and 
assurance on most of the routine methods currently em­
ployed by cytogenetic and molecular laboratories. The fol­
lowing standards, decided after extensive discussion, 
should be considered as minimum acceptable criteria, 
and, therefore, any laboratory consistently operating only 
to the minimum standard may be in danger of failing to 
maintain a satisfactory performance over an extended 
period of time. The ethical issues concerned in prenatal 
diagnosis have been subject to thorough discussions with­
in EU leading to a report by the Group of Advisors on the 
Ethical Implications of Biotechnology of the European 
Commission [3].
Status of QA in the Participating Countries
Austria: Laboratories have their own internal stan­
dards and no national EQA programme exists. Some labo­
ratories, have, however, participated in the German pro­
grammes. The Austrian Society of Human Genetics was 
formed in 1996 and one of its most immediate aims is to 
define standards for genetic services.
Belgium: All genetic service is regulated by law. The 
centres of human genetics are licensed by the Ministry of 
Health, and quality control is the responsibility of the 
High Council of Anthropogenetics. Clinical genetic activi­
ties and genetic diagnostic tests may only be performed in 
these centres.
Denmark: National guidelines regarding indications 
for prenatal diagnosis have been set forward by the 
National Board of Health. No formal regulations of inter­
nal quality assessment (IQA) or EQA guidelines exist for 
genetic laboratories. However, one laboratory is at 
present seeking accreditation.
Finland: The Finnish Society for Medical Genetics has 
published guidelines on clinical genetic service in 1986 
and updated them twice. Standards for laboratory IQA 
will be included in the next version of these guidelines. All 
eleven cytogenetic laboratories, seven of which perform 
prenatal tests, take part in EQA programmes arranged by 
a private non-profit company (Labqualtiy Ltd.). One lab­
oratory participate in the US CAP system. EQA is, so far, 
not available for molecular genetics. Eight laboratories in 
Finland provide maternal serum screening for Down’s 
syndrome. One of these has joined UK NEQAS and 
another MUREX (UK) for EQA. A national training pro­
gramme for scientists in medical laboratory genetics has 
recently been established.
France: Accreditation of genetic laboratories is 
awarded by the Ministry of Health. All laboratories must 
have IQA programmes. There are regulations regarding
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informed consent and genetic counselling. The cytogenet­
ic laboratories have no EQA programmes; molecular lab­
oratories participate on a voluntary basis in international 
EQA programmes and are developing national guide­
lines.
Germany: Quality assurance in laboratory medicine is 
stipulated by law, by guidelines, and by reimbursement 
agreements between Federal Association of Physicians 
and insurance companies. The German Association of 
Medical Geneticists has sought to improve the cytogenet­
ic standards by carrying out workshops to introduce new 
methods, training courses and by developing guidelines 
for laboratory work. Since 1990 the Association has pro­
vided EQA for cytogenetic laboratories, and since 1993 
for an increasing number of molecular investigations; par­
ticipation in these programmes is so far voluntary, but is 
strongly encouraged by the professional organisations.
Since 1993, special 5-year training programmes are in 
operation for medical doctors and scientists, which cover 
all aspects of general, clinical, and molecular genetics and 
cytogenetics. Certifications are given by the professional 
associations of physicians (Facharzt fur Humangenetik), 
and the German Society of Human Genetics (Fachhu- 
mangenetiker), respectively. In the future, only geneticists 
with one of these certifications will be eligible for appoint­
ment as laboratory directors.
Greece: No formal regulation of laboratory standards 
exists. IQA is up to the laboratory itself. No national EQA 
programmes exist.
Italy: In 1995, the Italian Association of Medical Cyto­
geneticists issued guidelines for clinical cytogenetics, 
which have been updated in 1996. As to EQA, the Asso­
ciation has approved a site visit programme, which 
should be implemented within approximately 1 year. Par­
ticipation to the EQA programme will be on a voluntary 
basis, with expenses covered by the requesting laborato­
ries. National guidelines concerning the general investiga­
tion have not been instigated so far, although documents 
on specific disorders (e.g. Huntington’s disease and famil­
ial adenomatous polyposis) already circulate or are in 
preparation. Molecular laboratories participate on a vol­
untary basis in international EQA programmes.
Luxembourg: No formal regulations exists; the only 
prenatal cytogenetic laboratory in the country has set IQA 
standards, but so far does not participate in EQA pro­
grammes.
The Netherlands: In 1992 the Dutch Society for Medi­
cal Genetics undertook to establish a document on QA for 
clinical genetic services. However, this document is main­
ly focused on counselling aspects. Therefore two commit­
tees representing cytogenetic and molecular genetics were 
then formed to formulate national guidelines for laborato­
ry serice. A document regulating cytogenetic services was 
issued in 1995 and a document on molecular genetics is 
under development. All Dutch laboratories are commit­
ted to the introduction of quality assurance systems which 
should make them eligible for accreditation in 2 or 3 
years. As yet, all genetic service is regulated by law and the 
seven clinical genetic centres present in the Netherlands 
are appointed by the Ministiy of Health.
Portugal: All centres have their own IQA programmes; 
no national EQA exists, and the performance of clinical 
laboratories is not regulated by law. Laboratories have 
participated in international EQA schemes. However, 
there is an interest among the laboratory professionals to 
develop national guidelines for both molecular genetics 
and cytogenetics.
Spain: In the absence of national legislation, and with 
the purpose of setting minimum criteria for cytogenetic 
services, a cytogenetics committee was formed in 1994 by 
the Spanish Association for Prenatal Diagnosis. This 
committee is currently engaged in the development of a 
self-financed EQA system, and in 1996 issued guidelines 
for good laboratory performance. For molecular biology, 
however, no national guidelines exist.
Sweden: In 1994 the Swedish Society for Medical 
Genetics issued guidelines involving IQA standards for all 
aspects, skills and tasks, undertaken in the discipline of 
clinical genetics, including recommendations for organi­
sation, staffing, cytogenetic and molecular Laboratory pro­
cedures, and recommendations for counselling. Formal 
EQA does not exist for genetic laboratories in Sweden. 
However, voluntary exchange of samples and comparison 
of results have been practised for many years.
Switzerland: The new federal health insurance law 
requires quality control in laboratory services, but it is not 
yet enforced in the field of medical genetics. The Swiss 
Society for Medical Genetics was appointed to establish 
the rules in this part of medicine. The latest general 
assembly delegated the task to the committee of quality 
control and accepted a revised model of half-yearly assess­
ment of randomly selected cases undertaken by an elected 
panel. The regulations of the case selection and the crite­
ria of quality judgement are presently being worked out.
United Kingdom: The EQA scheme for cytogenetics, in 
operation since 1982, is a member of the UK NEQAS 
consortium, a group including schemes from all major 
pathology disciplines. This scheme comprises a retro­
spective analysis of success rates and reporting times, and 
evaluation of slide quality and reports. A molecular genet-
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ics scheme, initiated by the Clinical Molecular Genetics 
Society in 1991, and now an approved independent 
scheme operates by the circulation of DNA samples; in 
1995, eight different disorders were included. The 
Schemes are advised by Steering Committees and perfor­
mance criteria established by an Advisory panel.
Clinical Pathology Accreditation (CPA UK ltd.) has 
recently taken the role of laboratory accreditation; genetic 
laboratories are included. Criteria assessed include organ­
isation and administration, staffing and direction as well 
as facilities and equipment, policies and procedures, staff 
development and training.
Through their Training and Accreditation Boards, the 
Association of Clinical Cytogeneticists (ACC) and the 
Clinical Molecular Genetics Society (CGMS) offer certifi­
cation following approved training. The ACC also offers a 
diploma by examination. The Royal College of Patholo­
gists offers the highest professional qualification in both 
molecular genetics and cytogenetics to scientific and med­
ical graduates. Membership is accepted as appropriate 
qualification for the Head of a laboratory,
Guidelines on Minimum Quality Standards in 
Prenatal Diagnosis
Prenatal diagnosis is a potential cause of considerable 
anxiety to a pregnant woman and her family, and, there­
fore, every woman undergoing an invasive prenatal proce­
dure must be offered genetic counselling by an appro­
priate professional well acquainted with the risks, benefits 
and limitations of the procedures.
1. Staffing
1.1. Staffing
Effective staffing is a prerequisite for providing a high- 
quality service. This includes both appropriate training 
and qualification for the personnel performing the analy­
sis and supervision, and a level of staffing which enables 
the laboratory to present results without unnecessary 
delay.
1.2. Medical Collaboration
The laboratory must have access to medical expertise 
on a regular basis. A clinical consultant should be avail­
able within a time scale appropriate to the urgency of any 
foreseeable clinical situation. Senior clinical and laborato­
ry specialists should have sufficient interdisciplinary 
training to ensure an adequate working knowledge of each 
other's speciality.
1.3. Laboratory Supervision
A laboratory supervisor must have adequate educa­
tion, qualification and experience for his/her position. 
There should be evidence that less qualified staff are 
supervised by an appropriate qualified person.
1.4. Technical Staff
Staff members working with prenatal samples should 
have adequate education for the type of investigation they 
are performing.
1.5. Workload Recommendations
1.5.1. A minimum annual workload for a member of 
staff undertaking chromosome analyses is 200-250 pre­
natal samples a year. Estimating the workload is in­
fluenced by the degree of automation of preparations, 
karyotyping, ratio CVS/AC, if photographic work is in­
cluded or not. Sufficient time should be allocated to 
developmental work. Cleaning and support duties are not 
included in this estimation, but the number of staff should 
be sufficient to ensure that no unnecessary delays occur in 
the processing of samples.
In order to ensure continuity of service during ab­
sences and vacations, it is recommended that a cytogene­
tics laboratory process at least 400 samples per year (in­
cluding all sample types) and employ a minimum of two 
experienced cytogeneticists.
1.5.2. For molecular studies, workload estimates are im­
possible to calculate, since prenatal samples comprise part 
of family studies; it is essential that the laboratory has expe­
rience from postnatal investigations of the disease to be 
investigated prenatally and has sufficient time to undertake 
the necessary developmental work. Continuity of the ser­
vices must be maintained during absences and vacations.
1.6. Certifications
1.6.1. Staff should have adequate education for their 
tasks in the laboratory. The laboratory should have a 
training programme with written protocols for each as­
pect of the laboratory work undertaken, to include infor­
mation and advice on health and safety. Each trainee 
should have a named tutor responsible for ensuring that 
training is given to the appropriate standard.
1.6.2. Each member of staff should have a written job 
description.
1.6.3. The laboratory should have a register to include 
information on basic education, attended courses, etc. for 
each member of staff.
1.6.4. Staff should be encouraged to gain appropriate 
professional qualifications.
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2. Equipment and Facilities
2.1. Minimum Standards
All equipment and facilities in the laboratory should 
fulfil the requirements for European Community stan­
dards (CE approved).
2.1.1. To maximise success rate all equipment should 
exist at least in duplicate, i.e., the laboratory should be 
equipped with at least two incubators, two centrifuges, 
two microscopes, etc.
2.1.2. All incubators and other critical equipment 
should be fitted with alarm systems.
2.1.3. Lack of space or appropriate equipment must 
not be a rate or quality-limiting factor in culture or analy­
sis.
2.2. Operating Instructions
All equipment should have operating instructions in 
languages understood by all staff. It is the responsibility of 
the Supervisor to ensure that all staff are appropriately 
trained and can read and understand those operating 
instructions.
3. Laboratory Procedures
3.1. Cell Culture
Before a CVS sample is cultured it must be carefully 
dissected and as far as possible separated from maternal 
tissue.
3.1.1. Long-term cultures: Duplicate cultures are rec­
ommended for all prenatal samples. The cultures should 
be kept in separate incubators, and preferably be handled 
separately to minimise the risks of contamination and 
other disturbances in culturing. If possible, cultures 
should be kept until the final report is written. Facilities 
should be available for freezing viable cells in unresolved 
cases of abnormal fetal pathology.
3.1.2. Short-term CVS: If an initial cytogenetic diag­
nosis is to be made on short-term preparations, a long­
term culture should be available for confirmation in order 
to minimise problems of interpretation.
3.1.3. Fetal blood samples: A test should be performed 
to check that the samples originates from the fetus. Sever­
al haematological methods are available.
3.2. Cytogenetic Analysis
3.2.1. Cytogenetic analysis: All cases should be ana­
lysed using a banding technique. A standardised method 
for assessing banding quality should be used, with an 
agreed minimum standard which may vary depending on 
the reason for referral. Several useful systems have been 
developed to help assess banding quality. In no case
should a report be issued without cells having been sub­
jected to full analysis of the banding pattern of the whole 
chromosome complement. Full analysis must be pursued 
to the satisfaction of the Supervisor that numerical and 
structural abnormalities have been excluded to a level 
appropriate to the referral reason. It is unreasonable to 
expect all cases of true fetal chromosome mosaicism or 
small structural rearrangements to be detected by routine 
levels of analysis.
3.2.2. Mosaicism: A written procedure for delineating 
different types of mosaicism should be drawn up for guid­
ance within the laboratory. In an amniotic culture, detec­
tion of a mosaic chromosomal change must be followed 
up by extensive examination of cells from an independent 
culture, or from independent colonies. Failure to confirm 
the abnormal cell line provide reassurance o f a normal 
pregnancy but, depending on the chromosome involved 
and the nature of the abnormality, supplementary investi­
gations may be appropriate. For CVS, the significance of 
mosaicism depends on the distribution of the abnormality 
amongst cells in direct and cultured preparations, and the 
chromosomes involved. The possibility of fetal uniparen­
tal disomy in some cases cannot be ignored, and addition­
al tests may be required to resolve the uncertainty.
Single cell abnormalities may be discounted following 
sufficient additional screening.
3.2.3. Storing: For each sample at least one, preferably 
two metaphases should be documented.
3.2.4. Referrals: The laboratory should have policies 
for referral elsewhere in cases requiring specialised exper­
tise which it cannot provide, e.g., for FISH analyses.
3.3. DNA Analysis
3.3.1. CVS specimens are desirable for molecular 
analyses in high-risk pregnancies. If CVS material is used 
for DNA analysis it is essential that the sample is carefully 
dissected and fetal and maternal tissue separated imme­
diately after biopsy is performed. A written document and 
a label with the sample must clearly state whether or not 
such separation has taken place.
3.3.2. Given sufficient material, it is advisable that the 
sample is divided into two parts to be handled sepa­
rately.
3.3.3. For all prenatal samples, appropriate positive 
and negative controls should be run simultaneously.
3.3.4. A check for maternal contamination must be 
performed if the fetal and maternal genotypes appear to 
be identical. If material contamination is demonstrated, a 
second sample must be requested.
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3.3.5. DNA preparations should be performed using 
established protocols.
3.3.6. Probes/primers used should be well docu­
mented.
3.3.7. Southern transfers should be documented and 
include size markers.
3.3.8. Hybridisation should be performed according 
to established protocols.
3.3.9. PCR analysis should be organised to minimise 
the possibilities for contamination.
3.3.10. For PCR reactions blanks should be included 
together with size markers.
3.4. Post-Abortion Follow-Up
If fetal morphology does not confirm the laboratory 
finding, follow-up samples should be appropriately ana­
lysed. Follow-up on all abnormal cases is recommended.
3.5. Methodological Development
In view of the rapidly changing practices and techno­
logies, each laboratory should have a plan for develop­
ment and introduction of new methods and techniques.
4. Quality Assurance
4.1. Procedures
4.1.1. The laboratory should have a reliable method of 
identifying samples and keeping them separate in order to 
minimise contamination, and cross- or mislabelling when 
processing.
4.1.2. All procedures performed in the laboratory 
should be traceable. It should be possible to reconstruct 
who did what on a given day, what batches of reagents, 
what protocols were used, etc.
4.2. Protocols
All protocols and methods used should be comprehen­
sively documented. Changes in methods and protocols 
should be dated so that for every procedure it is possible 
to deduce which protocol was used on a given day.
4.3. Education
It is the responsibility of the Head of Department to 
ensure that the staff are able to participate in a continuing 
educational programme relevant to the repertoire of the 
laboratory.
4.4. Nomenclature
The laboratory must follow accepted standard nomen­
clatures. Cytogenetic laboratories must follow the latest 
edition of ISCN.
4.5. Annual Success Rates
4.5.1. Amniotic fluid and long-term CVS cultures for 
cytogenetic analyses: >98%.
4.5.2. Direct CVS for cytogenetic analyses: 90% on 
samples of adequate size.
4.5.3. DNA investigations: >98% on samples of ade­
quate size.
4.5.4. For fetal blood samples minimum figures are 
not available because of the diversity of samples.
4.6. Checking and Authorisation
4.6.1. Record of cultures and analyses should be 
signed by responsible persons involved in the processing. 
Before any report leaves the laboratory it should be 
checked and signed by an authorised person.
4.6.2. Stringent checking procedures should be in 
place in order to minimise errors in patient or sample 
identity. The laboratory should have a documented sys­
tem for checking at critical points in the processing of a 
sample.
4.7. Internal Quality Assessment
Setting, monitoring, and maintaining laboratory stan­
dards (IQA) should be the duty of the supervisor or anoth­
er appropriately qualified named person. The head of the 
laboratory/department should receive frequent informa­
tion regarding current laboratory performance. Where 
standards fall below the agreed criteria it should be possi­
ble to identify the underlying reasons and instigate mea­
sures to rectify any deficiencies.
4.8. External Quality Programme
The laboratory should participate in EQA programmes 
appropriate to its full repertoire of tests or analyses.
4.9. Site Visits
Site visits performed by a peer group instead of, or as a 
complement to, EQA should be documented, and the rec­
ord of the visit made available to the profession. The vis­
iting group, preferably selected by an organisation outside 
the laboratory, should include persons with experience 
across the full repertoire of the laboratory.
4.10. Revision
Annual re-evaluation of protocols, procedures, and 
manuals is recommended. All changes should be dated 
and signed by the person responsible for IQA. Obsolete 
versions should be retained for at least 10 years.
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4.11. Health and Safety
A laboratory safety committee should be constituted to 
oversee safe working practices in order to minimise inju­
ries and infections occurring to staff, patients and vis­
itors.
5. Reports
5.1. Standardisation
Reports should be issued in a standardised manner, 
clear to read for the non-specialist.
5.2. Report Information
The report should include the following information
5.2.1. Cytogenetic reports
-  date of referral and reporting;
-  identification of laboratory and patient;
-  tissue studied;
-  whether the chromosome complement is normal or 
not;
-  a comprehensive written description of any chromo­
some abnormality;
-  the correct designation of the karyotype, according to 
the current issue of ISCN;
-  a written interpretation understandable by the non­
specialist;
-  signature of the person responsible for the results.
5.2.2. Molecular reports
-  date of referral and of reporting;
-  identification of laboratory and patient;
-  type and quality of tissue studied;
-  disease tested;
-  target sequence studied;
-  method used;
-  outcome of analyses;
-  a written interpretation understandable by the non­
specialist;
-  signature of the person responsible for the results.
5.2.3. Substandard analysis: In cases where the quality 
or level of analysis fails to achieve agreed standards, the 
report should be appropriately qualified to explain the 
limitations of the results.
5.3. Reporting Time
5.3.1. Cytogenetic reports: There should be no delay in 
reporting the results due to insufficient staffing; the report 
should be sent out not later than the day after the analysis 
is finished. 90% of long-term CVS and amniotic cultures 
should be reported within 21 days. For short-term CVS 
culture reports should be issued within 7 days.
5.3.2. Molecular reports: Reporting time should be a 
short as possible with the technique used. There should b 
no delay in reporting the results due to insufficient stafi 
ing; the report should be sent out not later than the da 
after the anaylsis is finished.
PCR analyses should be reported within 7 days.
Southern blot analyses should be reported within b  
days.
6. Records
In many countries, storage and filing of patient date 
and tissues are subject to National regulations. The fol­
lowing recommendations apply only when in concurrence 
with such regulations:
6.1. Retention of Documentation
Filing should be undertaken in a logical and consistent 
manner. The file must contain a unique sample number, 
and patient identification should include the full name 
and at least two of the following: date of birth, hospital 
identification number, social security number, address 
including postal code. The file must contain comprehen­
sive information on tests performed and on how to 
retrieve documentation and material.
6.2. Specimen Storage
If possible, cultures should be kept until the final report 
is written. Cell cultures with unique rearrangements 
should be stored until after delivery, preferably indefinite­
ly. Relevant information to trace the processing of the 
case should be saved for at least 5 years, but preferably, 
indefinitely. DNA samples useful for further analyses 
should be stored preferably indefinitely after informed 
consent of the patient.
6.3. Storage Times
All information necessary to trace the handling of the 
case should be stored for at least 2 years; results, including 
computerised images or photo-negatives, indefinitely. 
Where the request form contains clinical information not 
readily accessible in the patients notes but used in the 
interpretation of test data, the request should be kept per­
manently.
6.4. Confidentiality
Confidentiality of genetic information is of utmost 
importance. Filing of records should incorporate a securi­
ty system in order to minimise access by unauthorised 
persons.
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Discussion
These guidelines, to be considered as minimum ac­
ceptable standards for prenatal diagnosis, are intended to 
assist in the development of national standards. Tradition 
and regulations differ throughout Europe so in some 
instances these guidelines may not be in accordance with 
national/federal laws and regulations. In such cases, of 
course, those regulations already form the basis upon 
which the national standards operate.
The participants failed to reach agreement on the need 
to undertake chromosome analysis in cases on which the 
primary reason for referral was for non-cytogenetic rea­
sons. On the one hand, analysis may not be justified on 
grounds of the low risk of abnormality in relation to the 
effort and cost of the analysis; the opposing argument is 
that optimum information should be extracted from sam­
ples taken by invasive procedures which have a clinical 
risk to the patient and pregnancy.
Formal professional training and qualification in labo­
ratory and/or clinical aspects of medical genetics is not 
available in all European countries, and establishment of 
suitable specialist training programmes is to be strongly 
encouraged. The need for international collaboration in 
efforts to achieve consistent high standards should also be 
stressed.
For laboratory specialists, training should include at 
least a basic level of clinical knowledge, while the clinical 
specialist should have some familiarity with the opera­
tion of the laboratory. Thus, a closely co-ordinated colla­
borative approach between the laboratory and clinic may 
be maintained, and is essential in ensuring the availabili­
ty of the best information to the pregnant woman and her 
family.
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Department of Clinical Genetics 
Kennedy Institute 
Gl. Landevej 7
DK-2600 Glostrup (Denmark)
Tel. +45 43260100, fax +45 43431130 
e-mail kbn@kennedy.dk
Lars Vejerslev
Department of Clinical Genetics 
Kennedy Institute 
Gl. Landevej 7
DK-2600 Glostrup (Denmark)
Tel. +45 43260100, fax +45 43431130
e-mail eucromic@kennedy.dk
Finland 
Harriet von Koskull 
Laboratory of Prenatal Diagnosis 
Department of Obstetrics and Gynecology 
University Hospital 
Haartmaninkatu 2 
FIN-002 90 Helsinki (Finland)
Tel. +358 9 471 36 04, fax +358 9 471 49 06
e-mail harriet.koskull@hyks.mailnet.fi
France 
Emmanuelle Giraudon 
Laboratoire de Biochimie 
Hôpital Henri-Mondor 
51, avenue Maréchal-de-Lattre-de-Tassigny 
F-94 070 Créteil (France)
Tel. +33 01 49 81 28 61, fax +33 01 49 81 28 42 
e-mail goosens@im3.inserm.fr
Robert Saura
Unité de Cytogénétique et de Diagnostic Prénatal 
Centre Hospitalier Régional 
Place Amélie-Raba-Léon 
F-33 076 Bordeaux Cedex (France)
Tel. +33 05 56 79 55 58, fax +33 05 56 79 60 38
e-mail rsaura@alienor.fr
Germany 
Karsten Held 
Medizinische Genetik 
Lademannbogen 61 
D-22 339 Hamburg (Germany)
Tel. +49 40 538 05 800, fax +49 40 538 05 803
Clemens R. Müller-Reible 
Institut fur Humangenetik 
Biozentrum 
Am Hubland
D-97074 Würzburg (Germany)
Tel. +49 931 888 4063, fax +49 931 888 4069
e-mailcrm@biozentrum.uni-wuerzburg.de
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Greece 
Caterina Metaxotou 
Genetic Department 
First Department of Pediatrics 
Agia Sophia Childrens’ Hospital 
Athens 605 (Greece)
Tel. +30 2 77 95 553, fax +30 1 77 95 762 
Italy
Maurizio Genuardi 
Instituto di Genetica Medica 
Università Cattolica del San Cuore 
Largo Francesco Vito 1 
1-00168 Roma (Italy)
Tel. +39 6 30 54 327, fax +39 6 30 50 031 
e-mail E067GN016 AREA. B A. CNR. IT
Giuseppe Piombo 
Centro Genetica Umana 
VA. Volta lOv 
Ospedale Galliera
1-16128 Genova (Italy)
Tel.+39 10 56 32 394, fax +39 10 56 32 628
Luxembourg 
François Schneider 
Laboratoire National de Santé 
L—1011 Luxembourg (Luxembourg)
Tel. +352 49 11 91, fax +352 40 42 38
The Netherlands 
Dominique Smeets 
Department of Human Genetics 
PO Box 9101
NI^6500 HB Nijmegen (The Netherlands) 
Tel.+31 24361 41 04,fax+31 343 5421 51 
e-mail D.Smeets@antr.azn.nl
Ans van den Ouweland 
Department of Clinical Genetics 
Erasmus University 
POBox 1738
NL-3000 DR Rotterdam (The Netherlands) 
Tel.+31 10 40 87 197, fax+31 1040 87 200
e-mail vandenouweland@kgen.fgg.azr.nl
Portugal 
Paula Pacheco
Molecular Biology Laboratory 
Instituto Nacional de Saúde Dr Ricardo Jorge 
Avenida Pedro Cruz 
P—1699 Lisboa (Portugal)
Tel.+351 1 757 91 59, fax+351 1 75 90 441
Hildeberto Correia
Cytogenetics Laboratory
Instituto Nacional de Saúde Dr Ricardo Jorge
Avenida Pedro Cruz
P - 1699 Lisboa (Portugal)
Tel.+351 1 757 91 59, fax+351 1 75 90 441
Switzerland 
Franz Binkert
Instituí fur Medizinische Genetik
Ramistrasse 74
CH-8001 Zürich (Schweiz)
Tel. +41 1 257 25 2 i} fax +41 1 262 04 70
e-mail binkert@medgen.unizh.ch
Spain 
Joaquina Gabarrón
Centro de Bioquímica y Genetica Clínica 
Conjunto Residencial 
Apartado 61
B—30100 Murcia (Spain)
Tel. +34 68 30 72 27, fax +34 68 30 50 05
Pia Gallano
Servicio de Genetica Molecular 
Hospital de Sant Pau 
Avenida San Antoni Maria Claret 167 
E-08025 Barcelona (Spain)
Tel. +34 3 291 93 61, fax +34 3 291 91 92
Sweden 
UlfKristoffersson 
Department of Clinical Genetics 
University Hospital 
S—221 85 Lund (Sweden)
Tel. +46 46 17 33 63, fax +46 46 13 10 61 
e-mail Ulf.Kristoffersson@kl ingen.lu.se
Maria Anvret
Department of Clinical Genetics
Karolinska Hospital
S-171 76 Stockholm (Sweden)
Tel. +46 8 729 39 31, fax +46 8 32 77 34 
e-mail manv@gen.ks.se
United Kingdom 
Rod Howell
Regional Cytogenetics Centre 
Southmead Hospital 
Bristol BS10 5NB (UK)
Tel. +44 117 959 55 69, fax +44 117 959 55 72
Susan Stenhouse
Molecular Laboratory, Ridley Building 
Claremont Place
Newcastle-upon-Tyne NE1 7RU (UK)
Tel. +44 191 222 6821, fax+44 191 222 6662 
e-mail S.A.R. Stenhouse(a)ncl.ac.uk
Appendix 2
Guidelines for Quality Assessment in Prenatal Diagnosis
Referred to When Developing These Guidelines
Australasia: Guidelines for standards in cytogenetic laboratories 
(1994). Human Genetics Society of Australasia, 1994.
Germany: Entwurfsfassung: Leitlinien des Berufsverbandes Me­
dizinische Genetik e.V., 1996.
Italy: Diagnostica Citogenetica, Consensus 1995. Associazione 
Italiana di Citogenetica Medica, 1995.
The Netherlands: De kwalitet van diagnosiisch cytogenetisch 
onderzoek: Een inventarisate van voorwaarden, normen en toetsen: 
Landelijk Overleg Cytogenetica (LOC), 1995.
Sweden: Riktlinjer for kvalitetssakring i klinisk genetik. Svensk 
Fòrening for Medicinsk Genetik 1994.
UK: Guidelines for Clinical Cytogenetics. UK NEQAS and the 
Association of Clinical Cytogeneticists, 1994.
USA\ Standards and guidelines: Clinical Genetics Laboratories. 
The American College of Medical Genetics. Laboratory Practice 
Committee, 1996.
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